vision loss with tirzepatide eye issues Comparative ocular outcomes of versus other anti-obesity medications in people obesity loss: GLP-1 drugs like – Vision loss risks in patients

While still exploratory and not considered a core asset at this stage, the initiative reflects a broader strategy aimed at building diversified platform capabilities across multiple high-growth therapeutic areas

Neither is FDA approved for weight loss, and neither is backed by strong clinical evidence

That means their bodies may feel stronger effects from the same dose, which could explain why some women experience more side effects

Were reviewing future options, but currently prescription medications are paid by the patient

Regular monitoring is essential when taking Saxenda and sertraline together to ensure both safety and therapeutic effectiveness

Jadhav et al